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ABSTRACT 
Maple syrup urine disease (MSUD) is an autosomal recessive inherited metabolic disorder 
caused by malfunction of the branched-chain α-ketoacid dehydrogenase complex (BCKDH). 
This enzyme complex participates in the catalyzing metabolisms of the branched-chain α-
ketoacids, the second step of the degradation of branched-chain amino acids. Impaired activities 
of the BCKAD complex lead to an increase of the levels of branched- chain amino acid such as 
leucine, valine, and isoleucine in the blood. In children with maple syrup urine disease, catalysis 
of the metabolisms of some amino acids failed to be implemented, leading to an accumulation of 
the amino acids which has been shown as one of the causes of neurological complications, 
intellectual disabilities, and nervous paralysis or even death. Pathogenic mutations normally 
occur in BCKDHA, BCKDHB, DBT and DLD genes which encode the E1α, E1β, and E2 subunits 
of the BCKDH complex. In the present study, a homozygous mutation in the BCKDHB gene (c. 
1016C>T) in a pediatric patient with MSUD diagnosed at The National Hospital of Pediatrics 
was identified using whole exome and Sanger sequencing methods. As a result, the inheritance of 
the homozygous mutation related to MSUD in BCKDHB gene within the pedigree of the 
patient’s family was determined. The results indicated that the mutation in the BCKDHB gene 
was inherited from both of the patient’s parents. In addition, this finding provides an important 
scientific basis to  researches on MSUD in the Vietnamese population. 
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INTRODUCTION 
Maple syrup urine disease (MSUD), an 
inherited amino acid metabolism disorder, 
belongs to a group of rare diseases in newborn 
babies caused by genetic abnormalities in 
BCKDHA, BCKDHB, DBT and DLD genes, 
which encode an inherited amino acid 
metabolism disorder subunits of the branched 
α-ketoacid dehydrogenase complex 
(BCKAD). (Lee et al., 2008; Ali & Ngu, 
2018). The BCKDA complex composed of 
four different subunits E1α, E1β, E2 and E3 
necessary for oxidative decarboxylation of 
branched-chain α-keto acids. The mutational 
changes of these encoded genes lead to 
damage functions of the BCKAD complex, 
resulting in accumulation of branched-chain 
amino acids, including leucine, isoleucine, 
and valine. High accumulation of these amino 
acids could cause mental retardation and 
neurological impairment. The maple syrup 
urine disease, if  not detected early and treated 
timely, may lead to seizures, coma, and even 
death. Based on the genetic mutations, MSUD 
is classified into four types: type Ia 
(BCKDHA); type Ib (BCKDHB), type II 
(DBT) and type III (DLD) (Ali & Ngu, 2018). 
Since the first mutation in BCKDHA gene was 
detected in 1989 (Zhang et al., 1989), more 
than 283 mutations, scattering over BCKDHA, 
BCKDHB, DBT and DLD genes, been 
published in the Human Gene Mutation 
Database (HGMB). Mutations in BCKDHA 
and BCKDHB genes have been shown to be 
more common than in DBT and DLD genes. 
Mutations in MSUD patients can be either by 
homozygous or heterozygous (Ali & Ngu, 
2018). Based on various clinical 
presentations, MSUD is classified into five 
phenotypes, including classic, intermediate, 
intermittent, thiamine-responsive, and E3- 
deficient phenotypes (Ali & Ngu, 2018).  
About 75% of MSUD patients in  classic form 
are presented at the neonatal stage, presenting 
normally with neonatal-onset encephalopathy, 
maple syrup odor in the urine, increased 
branched chain amino acids in the blood and 
alpha-ketoacids in the urine (Guo et al., 2015). 
In this case, the activity of the BCKD enzyme 
complex is reduced to under 2% or 
undetectable (Kerstin et al., 2009; Blackburn 
et al., 2017). This  most dangerous type could 
be lethal if not detected early and treated 
promptly. MSUD is classified as a hereditary 
and very rare disease, appearing in both boys 
and girls with an estimated incidence rate of  
1/185,000 newborn babies (Ali & Ngu, 2018). 
However, the number could be much higher in 
countries with high rates of consanguinity 
(Kerstin et al., 2009; Jaafar et al., 2013). To 
date, the incidence rate of MUSD has not 
been reported in Vietnam. Among congenital 
metabolic disorders in Vietnam, MUSD is the 
most common and can be detected at the 
earliest age. Molecular genetic testing is 
essential for  diagnosis, early detection and 
treatment of MUSD patients. In the present 
study, genetic variants and inheritance of the 
mutations causing MSUD in a pediatric 
patient and his family members were studied 
using WES and Sanger. 
MATERIALS AND METHODS 
Patient 
Pediatric patient was diagnosed and 
treated for MSUD at 5 days of age at 
Department of Medical Genetics, 
Metabolism and Endocrinology, National 
Hospital of Pediatrics. Blood samples of the 
patient and other family members were 
collected with consent from the patient's 
parents. This study was performed in 
accordance with the Declaration of Helsinki, 
and the protocol  approved by the Ethics 
Committee of the Institute of Genome 
Research (No.18/QĐ-NCHG). 
Clinical presentation 
Clinical information, age of onset, clinical 
symptoms, results of routine biochemical tests 
and treatments were collected in the medical 
records of the Department of Medical 
Genetics, Metabolism and Endocrinology, 
National Hospital of Pediatrics. 
DNA preparation 
Blood samples were provided by The 
Department of Medical Genetics, Metabolism 
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and Endocrinology, National Hospital of 
Pediatrics. Total DNA was extracted from 
whole blood of MSUD patient and his family 
members using QIAamp DNA Blood Mini Kit 
(Qiagen, Germany). 
Whole exome sequencing and mutation 
analysis 
The DNA library was prepared using Kit 
Agilent SureSelect Target Enrichment 
(Macrogen) following the manufactures’ 
protocol and was sequenced on an Illumina 
NovaSeq 6000 platform (Illumina, CA, USA). 
Paired-end sequences were mapped to 
UCSC/hg19 reference human genome using  
Burrows–Wheeler Aligner 0.7.12. Duplicates 
were marked via Picard-1.130. Afterwards, 
variant data were analyzed using Genome 
Analysis Toolkit v3.4 and annotated using 
SnpEff v4.1 with database of dbSNP v142, 
1000Genome, ClinVar v 05/2015, ESP. Sift, 
Polyphen2 and Mutation Taster were used to 
evaluate the effect of genetic mutations on 
protein function. Mutation screening and 
analysis were performed on  BCKDHA, 
BCKDHB, DBT and DLD genes related to 
MSUD disease. 
Sanger sequencing 
An exon 9 region on BCKDHB gene 
(ENSG 00000083123) was amplified by PCR 
using specific primers (BCKB-F: 
5'TGACCTGTCGAAAGCGAGTT-3', BCKB 
-R:5’-CTTCTGGAATTGGCATGTGGA-3'). 
PCR reaction was performed with ingredients 
of 10X Dream Taq Buffer, 10 mM dNTP, 
2.5U/µl Dream Taq DNA polymerase and 10 
pmol/µl per primer, 100 ng/µl DNA template 
and thermal cycle: 95°C/12 minutes; (95
o
C/45 
seconds; 54
o
C/45 seconds; 72
o
C/45 seconds) x 
35 cycles; 72
o
C/8 min. The amplified PCR 
product was checked on 1.0% agarose gel. 
PCR product was sequenced using ABI3100 
(Applied Biosystems, USA). ClustalX 2 and 
BioEdit 7.0 were used to analyze the 
sequencing results to detect genetic  mutations 
by comparing WES sequencing results with 
reference BCKDHB gene sequence. 
RESULTS AND DISCUSSION 
Diagnosis and treatment 
The 5-day-old boy patient is the fifth child 
of a healthy family with normal parents. His 
two older sisters died at 27 and 23 days after 
birth and were diagnosed with MUSD. The 
patient was admitted at 5 days of age with a 
short cyanosis occurring alternately. 
Biochemical test showed high level of leucine 
(2323 μmol/l, normal: 17−155 μmol/l) and 
allo-isoleucine (74.9 μmol/l, normal: 64−294 
μmol/l). He was managed by stopping 
feeding, glucose infusion (10 mg/kg/min), 
thiamine supplement and hemofiltration. After 
48 hours of treatment, the patient was alert 
and leucine level was decreased  (432 μmol/l). 
At the age of 23 months, he had 2 recurrent 
episodes of MUSD and suffered from 
developmental delay with DQ of 65%. He has 
been monitored and examined periodically at 
Department of Medical Genetics, Metabolism 
and Endocrinology, National Hospital of 
Pediatrics. 
Mutation analysis by WES and Sanger 
sequencing 
Whole exome sequencing was performed 
to identify the genetic variants in the patient 
diagnosed with MSUD. Sequenced results 
were processed as presented  above. WES 
sequencing exposed a variant on the 
BCKDHB gene  was located on chromosome 
6, exon 9, at position 1016 on cDNA and 
position 339 in the polypeptide sequence 
(Table 1). 
 
Table 1. Variant c.1016C > T (p.Ser339Leu) on BCKDHB gene  
was identified by WES in MSUD patients 
Chrom Gene 
Type of 
mutation 
Zygosity Exon 
Coding DNA 
number 
Protein 
number 
dbSNP142_ID 
chr6 BCKDHB Missense HOM 9/11 c.1016C>T p.S339L rs398124561 
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The Sanger sequencing was used to 
confirm and analyze the variant in the 
patient and other family members (father, 
mother, brother, and sister). BCKB-F and 
BCKB-R primers were designed to amplify 
314 nucleotides on exon 9 of BCKDHB 
gene. Sanger sequencing showed a 
homozygous missense mutation c.1016C > 
T. This mutation occurred in exon 9, where 
C was replaced by T at position 1016 in 
cDNA, resulting in substitution of Ser 
(Serine) by Leu (Leucine) at position 339 of 
BCKDHB protein (Figure 1A). Other 
members of the patient’s family (father, 
mother, brother, and sister) were 
heterozygous mutation carriers and did not 
have any clinical presentation. Therefore, 
the patient with MUSD inherited two copies 
of the disease causing mutation from both 
his parents (Figure 1B, 1C). 
 
 
Figure 1. Pedigree and Sanger sequences of pS339L mutation. (A) Location of the mutation on 
exon 9 of BCKDHB gene. (B) Pedigree presentation of the family of patient. Heterozygous 
individuals, half black (p.S339L mutation). Patient with homozygous mutation, full black box. 
(C) Sanger sequence diagram 
 
The BCKDHB gene encodes one of the 
four subunits of the BCKAD complex, on the 
long arm of chromosome 6.  Mutations in 
BCKDHB gene lead to the classic form of 
MSUD also known as MSUD type Ib (Deepti 
et al., 2015; Ali & Ngu, 2018). Previous 
studies of MSUD indicated that the mutations 
normally occur in BCKHDB genes (Nellis, 
Danner, 2001; Skvorak, 2009; Theodoros et 
al., 2009). Gorzelany K et al. (2009) identified 
the mutation p.S339L that causes MSUD in 
Turkish pediatric patient at 18 days of age 
(Kerstin et al., 2009). This mutation was also 
found in an one month old Indian girl 
(Bashyam et al., 2012) and a 6 days old 
Malaysian girl (Ali & Ngu, 2018). Thus, 
S339L on BCKDHB gene was considered as a 
causative mutation of MSUD. In addition, 
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Ser339, located on helix α1 which was linked 
to Ser339 of E1b subunit via hydrogen 
bonding, was necessary for the polymerization 
process between the β’ and β subunit (Kerstin 
et al., 2009; Bashyam et al., 2012). Therefore, 
the replacement of serine-polar amino acid by 
leucine non-polar amino acid could disrupt 
hydrogen bonds, leading to alteration of the 
β'β arrangement and interaction between these 
two subunits (Wynn et al. , 2001; Kerstin et 
al., 2009; Bashyam et al., 2012). Hence, this 
mutation affected not only the structure, but 
also the function of BCKDHB protein and 
was considered to be the cause of MSUD. 
Mutation analysis of 3D protein structure 
model 
PDB software was applied to analyze and 
predict the effects of genetic variant on the 
BCKDHB structure. Based on the reference 
3D structure from PDB Bank with code 
1X7Y, we analyzed the change of amino acids 
in polypeptide chain when mutations appeared 
on the BCKHDB protein (Figure 2). In case of 
no mutation, there were four hydrogen bonds 
with amino acids Gly336 (two bonds) and 
Ser343 (two bonds) at Ser339 in the 
polypeptide chain. When the mutation occurs, 
the amino acid Ser339 was replaced by 
Leu339 at  Leu339, resulting in a loss of 
hydrogen bond with the amino acid  Gly336 
(Figure 2). This change affected the structure 
as well as the function of BCKHDB protein. 
In addition, Bashyam et al. (2012) used 
PyMOL to predict the effect of p.S339L 
mutation on the structure of BCKHDB 
protein. The result indicated that replacing a 
polar amino acid serine by a hydrophobic 
amino acid leucine lead to a break the 
hydrogen bond between two subunits of E1, 
resulting in a change of BCKHDB secondary 
structure (Bashyam et al., 2012). 
 
 
Figure 2. Model of BCKDHB 3D structure containing  p.S339L mutation in BCKDHB protein. 
Leu339 was marked by the brown arrow 
 
Figure 3. Amino acid sequence of protein of several species in comparison with human species 
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Moreover, multiple alignment of amino 
acid sequences of BCKDHB against mutation 
positions across species, including human 
(Homo sapiens), bonobo (Pan paniscus), 
white-cheeked gibbon (Nomascus 
leucogenys), sumatran orangutans (Pongo 
abelii), white whales (Delphinapterus leucas), 
narwhal (Monodon monoceros), marmota 
marmota (Marmota marmota marmota), 
Eurasian beaver (Castor fiber), European 
rabbit (Oryctolagus cuniculus), American 
beaver (Castor canadensis) was performed 
using ClustalX 2. Conservation analysis 
indicated that p.S339L mutation occurrs at 
highly evolutionary conserved position 
(Figure 3). 
CONCLUSION 
In the present study, we reported a 
homozygous missense mutation c.1016C>T 
(p.S339L) in BCKDHB gene, which was 
inherited from both parents in a boy patient 
with MSUD in Vietnam. His father, mother, 
brother, and sister did not show any clinical 
presentation due to the heterozygous 
mutation. The obtained result accurately 
determined the genetic cause of disease in 
the patient's family. In addition, this study is 
the basis for genetic counseling through 
newborn screening for diagnosis, early 
detection and treatment. 
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